Novovax Available for 12 – year olds from 5th September 2022

On 28 July 2022 the Therapeutic Goods Administration (TGA) provisionally approved Nuvaxovid (Novavax) COVID-19 vaccine (Biocelect Pty Ltd/Novavax Inc) for use in adolescents aged 12-17 years.

ATAGI has evaluated data on immunogenicity, efficacy, safety, and in international settings to make recommendations on the use of Novavax COVID-19 vaccine in this age group.

The Australian Government has accepted advice from ATAGI that adolescents aged 12-17 years can receive the Novavax COVID-19 vaccine for their primary course of COVID-19 vaccination. For more information, see the ATAGI recommendations on use of Novavax vaccine for adolescents aged 12-17 years.

Adolescents aged 12-17 years will be able to receive Novavax COVID-19 vaccine from 5 September 2022.